In the report of an analysis conducted by the investigators of the Montefiore Headache Center, Albert Einstein College of Medicine, New York, the need for specific protocols and guidelines appeared for the management of migraine during pregnancy. One of the common problems arise among pregnant women is the migraine, and it is difficult to treat this issue due to fears of medication teratogenicity and lack of evidence in this population.
A sigh of relief for migraineurs, the US FDA has recently approved Fremanezumab preventive treatment of migraine among adults. Migraine is one of the primary cause of disability that causes a severe headache with photophobia, phonophobia, nausea and vomiting.
A recent pilot study presents a simple electrophysiological marker that can potentially improve the prediction of migraine attacks. The problem of migraine led to considerable discomfort and decreased functioning for days at a time, involving the pre-ictal and post-ictal periods.
In recent research undertaken by the University of Campania "Luigi Vanvitelli", post-menopausal females with vertebral fractures showed significant improved HRQoL and decreased pain-related disability with Denosumab administration. Denosumab is a type of monoclonal antibody that hinders the osteoclast-mediated bone resorption by neutralizing the receptor activator of nuclear factor kappa-Β ligand (RANKL).
According to a recent narrative review published in the BMC Musculoskeletal Disorders, osteoarthritis of the elbow can be effectively and safely treated with the open and arthroscopic debridement procedures.
Elbow OA considered as one of the major disabling infirmity due to severe pain and loss of function. Open and arthroscopic debridement is the favoured approach to manage this critical condition, but no consent is available to define which therapy is befitted to which class of patient or stage of the elbow OA.
- 1 of 254